Miami-based eMed announced it has raised $200 million in funding at a $2 billion plus valuation, reinforcing its position as a growing player in employer-focused digital healthcare and population health management.
The Series A round was led by AON Consulting, Inc., with participation from a group of high-profile investors including Tom Brady, Jeff Aronin, Ara Cohen, Antonio Gracias, Joe Lonsdale, R.J. Melman, Tom Ricketts, and CEO Linda Yaccarino.
eMed operates a population health platform centered on clinically supervised GLP-1 and GIP programs for employers, an area seeing rapid demand as companies seek to manage rising healthcare costs tied to weight management and chronic conditions. The company positions itself as a leading provider in this category, combining clinical oversight with technology-driven engagement.
The company said proceeds from the financing will be used to advance its agentic AI platform and strengthen its balance sheet, while supporting the rollout of a new capitated healthcare model designed to help employers reduce overall healthcare spending. The platform focuses on improving adherence to GLP-1 therapies, which the company notes is critical to achieving meaningful health outcomes.
eMed reports more than 90% member adherence to treatment, significantly above industry norms, and says its programs deliver measurable results, including an average weight loss of 21 pounds and improvement in key health biomarkers for the vast majority of participants within six months.
The funding round underscores growing investor interest in healthcare platforms that combine AI, clinical programs, and employer-based distribution models to address cost and outcomes at scale.
KEY QUOTE:
“I believe eMed’s empathic agentic AI platform, combined with the strength of its people and partners, represents a true winning formula. That conviction is why I’ve chosen to invest both my time as Founding Chief Wellness Officer and my capital in the company,”
Tom Brady, Founding Chief Wellness Officer of eMed and Investor
